Immunology/Inflammation
Read More about this categoryShow Less
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
Research Areas
- 5-Lipoxygenase(17)
- Apoptosis(870)
- Cyclic GMP-AMP Synthase(7)
- TLR(131)
- Papain(1)
- PGDS(1)
- PGE synthase(26)
- SIKs(13)
- IκB/IKK(71)
- AP-1(15)
- KEAP1-Nrf2(62)
- NOD1(1)
- NF-κB(328)
- Interleukin Related(339)
- 15-lipoxygenase(2)
- Others(10)
- Aryl Hydrocarbon Receptor(43)
- CD73(17)
- Complement System(83)
- Galectin(13)
- IFNAR(65)
- NO Synthase(106)
- NOD-like Receptor (NLR)(74)
- STING(123)
- Reactive Oxygen Species(544)
- FKBP(17)
- eNOS(4)
- iNOS(29)
- nNOS(20)
- Glutathione(54)
- Adaptive Immunity(210)
- Allergy(118)
- Arthritis(34)
- Autoimmunity(181)
- Gastric Disease(94)
- Immunosuppressants(38)
- Immunotherapeutics(4)
- Innate Immunity(566)
- Pulmonary Diseases(109)
- Reactive Nitrogen Species(50)
- Specialized Pro-Resolving Mediators(49)
- Reactive Sulfur Species(28)
- BCL6(9)
- CD20(14)
- CD22(1)
- CD28(7)
- PSMA(15)
- FAP(26)
- Nuclear Factor of activated T Cells (NFAT)(2)
- Glycoprotein VI(2)
- Tim3(5)
- Hapten(1)
- Nectin-4(3)
- DOCK(4)
- MHC(13)
- Transmembrane Glycoprotein(36)
- TREM receptor(13)
- Inflammation or Immune System Disease(2)
- Musculoskeletal and Skin Disease(1)
- Fc Receptor (FcR)(14)
- IKZF Family(5)
- C-type Lectin-like Receptors (CTLRs)(10)
- Asialoglycoprotein Receptor (ASGPR)(3)
- Human leukocyte immunoglobulin (Ig)-like receptors (LILR)(1)
Products Related to Immunology/Inflammation(4844)
- GC74490TositumomabCAS: 192391-48-3
Tositumomab es un anticuerpo monoclonal IgG2a lambda murdirigido contra el antígeno CD20, que se encuentra en la superficie de linfocitos B normales y malignos.
- GC74491TucotuzumabCAS: 339986-90-2Purity: >95.00%
Tucotuzumab (Anti-EPCAM Recombinant anticuerpo) es un anticuerpo monoclonal específico de antígeno IgG1 que se dirige a la molécula de adhesión celular epitelihumana (EpCAM).
- GC74499TalacotuzumabCAS: 1826831-79-1Purity: >98.00%
Talacotuzumab (JNJ 56022473; CSL 362) es un anticuerpo monoclonal completamente humanide tipo IgG1, neutrdel cd123 que contiene una estructura Fc modificada.
- GC74501AdebrelimabCAS: 2247114-85-6Purity: >97.00%
Adebrelimab (SHR-1316) es un anticuerpo monoclonal humaniigg4 PD-L1 (PD-1/PD-L1).
- GC74515BenufutamabCAS: 2109730-69-8Purity: >98.00%
Benufutamab (GEN1029) es un anticuerpo agonista específico del receptor de muerte 5 (DR5).
- GC74518BrazikumabCAS: 1610353-18-8Purity: >95.00%
Brazikumab (AMG 139) es un anticuerpo monoclonal IgG2 humano, se une selectivamente a la subunidad P19 de IL-23, con un KD de 0,138 nM para la IL-23 humana.
- GC74523XeligekimabCAS: 2382921-73-3Purity: >95.00%
Xeligekimab (GR 1501) es un anticuerpo monoclonal humaniantiinterleucina humana 17A (IL-17A).
- GC74528UrabrelimabCAS: 2249722-58-3Purity: >98.00%
Urabrelimab (SRF231) es un anticuerpo monoclonal anti-CD47 humano que bloquea la interacción CD47-SIRP.
- GC74538SotevtamabCAS: 2411526-47-9Purity: >99.00%
Sotevtamab (16B5) es un anticuerpo monoclonal anti-clusterina IgG2 humanizado (mAb).
- GC74552GefurulimabCAS: 2456407-94-4Purity: >97.00%
Gefurulimab (ALXN-1720) es un anticuerpo biespecífico derivado del humano contra el complemento C5 y la albúmina que se une a C5 y bloquea su activación.
- GC74559InbakiceptCAS: 2135939-52-3Purity: >98.00%
Inbakicept es un dimérico humano IL-15 receptor alfa (IL-15 Ra) sushi dominio/humano IgG1 Fc proteína de fusión y es un complejo superagonista IL-15.
- GC74571LigufalimabCAS: 2428381-55-7Purity: >98.00%
Ligufalimab (AK 117) es un anticuerpo monoclonal IgG4 anti-CD47 humanizado.
- GC74585ObexelimabCAS: 1690307-05-1Purity: >95.00%
Obexelimab (XmAb5871) es un anticuerpo anti-CD19 humanizado.
- GC74588PlamotamabCAS: 2138442-31-4Purity: >99.00%
Plamotamab (XmAb-13676) es un anticuerpo humano biespecífico (bsAb) que se une a CD3 y CD20.
- GC74605Simlukafusp alfaCAS: 1776942-10-9Purity: >95.00%
Simlukafusp alfa (FAP-IL2v) es una inmunoocitocina que comprende un anticuerpo contra la proteína de activación de fibroblafibro(FAP) y una variante de IL-2 que solo se une a IL-2R α α.
- GC74607Efineptakin alfaCAS: 2026634-47-7Purity: >99.00%
Efineptakin alfa (NT-17) es una IL-7 humana recombinde acción prolongada.
- GC74612EpcoritamabCAS: 2134641-34-0Purity: >99.00%
Epcoritamab (GEN3013) es un anticuerpo IgG1 biespecífico que redirige las células t hacia las células tumorales CD3 − CD20+.
- GC74614Eftozanermin alfaCAS: 1820660-69-2Purity: >95.00%
Eftozanermin alfa (ABBV-621) es un agonista del receptor de ligandos (TRAIL-R) que induce apoptosis relacionado con el factor de necrosis tumoral de segunda generación.
- GC74620Zilovertamab vedotinPurity: >98.00%
Zilovertamab vedotin (VLS-101) es un noveanticuerpo-fármaco conjuque comprende el anticuerpo monoclonal humanizilovertamab y la citotoxina antimicrotúbulos monometl vedotina.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC74488 | Sirukumab | 1194585-53-9 | >95.00% | |
Sirukumab (CNTO-136) es un anticuerpo monoclonal humanianti-il6 (relacionado con interleucina) IgG1κ. | ||||
| GC74490 | Tositumomab | 192391-48-3 | - | |
Tositumomab es un anticuerpo monoclonal IgG2a lambda murdirigido contra el antígeno CD20, que se encuentra en la superficie de linfocitos B normales y malignos. | ||||
| GC74491 | Tucotuzumab | 339986-90-2 | >95.00% | |
Tucotuzumab (Anti-EPCAM Recombinant anticuerpo) es un anticuerpo monoclonal específico de antígeno IgG1 que se dirige a la molécula de adhesión celular epitelihumana (EpCAM). | ||||
| GC74499 | Talacotuzumab | 1826831-79-1 | >98.00% | |
Talacotuzumab (JNJ 56022473; CSL 362) es un anticuerpo monoclonal completamente humanide tipo IgG1, neutrdel cd123 que contiene una estructura Fc modificada. | ||||
| GC74501 | Adebrelimab | 2247114-85-6 | >97.00% | |
Adebrelimab (SHR-1316) es un anticuerpo monoclonal humaniigg4 PD-L1 (PD-1/PD-L1). | ||||
| GC74515 | Benufutamab | 2109730-69-8 | >98.00% | |
Benufutamab (GEN1029) es un anticuerpo agonista específico del receptor de muerte 5 (DR5). | ||||
| GC74518 | Brazikumab | 1610353-18-8 | >95.00% | |
Brazikumab (AMG 139) es un anticuerpo monoclonal IgG2 humano, se une selectivamente a la subunidad P19 de IL-23, con un KD de 0,138 nM para la IL-23 humana. | ||||
| GC74523 | Xeligekimab | 2382921-73-3 | >95.00% | |
Xeligekimab (GR 1501) es un anticuerpo monoclonal humaniantiinterleucina humana 17A (IL-17A). | ||||
| GC74528 | Urabrelimab | 2249722-58-3 | >98.00% | |
Urabrelimab (SRF231) es un anticuerpo monoclonal anti-CD47 humano que bloquea la interacción CD47-SIRP. | ||||
| GC74538 | Sotevtamab | 2411526-47-9 | >99.00% | |
Sotevtamab (16B5) es un anticuerpo monoclonal anti-clusterina IgG2 humanizado (mAb). | ||||
| GC74552 | Gefurulimab | 2456407-94-4 | >97.00% | |
Gefurulimab (ALXN-1720) es un anticuerpo biespecífico derivado del humano contra el complemento C5 y la albúmina que se une a C5 y bloquea su activación. | ||||
| GC74559 | Inbakicept | 2135939-52-3 | >98.00% | |
Inbakicept es un dimérico humano IL-15 receptor alfa (IL-15 Ra) sushi dominio/humano IgG1 Fc proteína de fusión y es un complejo superagonista IL-15. | ||||
| GC74566 | Keliximab | 174722-30-6 | >98.00% | |
Keliximab (SB-210396) es un anticuerpo monoclonal anti-CD4 humano/macaco IgG1 quimérico con un valor de Ki de 1,0 nM para CD4 soluble. | ||||
| GC74571 | Ligufalimab | 2428381-55-7 | >98.00% | |
Ligufalimab (AK 117) es un anticuerpo monoclonal IgG4 anti-CD47 humanizado. | ||||
| GC74572 | Lilotomab | 1453362-55-4 | >98.00% | |
Lilotomab (0-40 µg/mL; 12 días) reduce la supervivencia clonogénica de las células DOHH2 y Ramos. | ||||
| GC74585 | Obexelimab | 1690307-05-1 | >95.00% | |
Obexelimab (XmAb5871) es un anticuerpo anti-CD19 humanizado. | ||||
| GC74588 | Plamotamab | 2138442-31-4 | >99.00% | |
Plamotamab (XmAb-13676) es un anticuerpo humano biespecífico (bsAb) que se une a CD3 y CD20. | ||||
| GC74590 | Pozelimab | 2096328-94-6 | >99.00% | |
Pozelimab (REGN3918) es un anticuerpo monoclonal IgG4 anti-C5 totalmente humano. | ||||
| GC74599 | Cobolimab | 2022215-65-0 | >98.00% | |
Cobolimab (TSR-022) es un anticuerpo monoclonal anti-TIM-3. | ||||
| GC74605 | Simlukafusp alfa | 1776942-10-9 | >95.00% | |
Simlukafusp alfa (FAP-IL2v) es una inmunoocitocina que comprende un anticuerpo contra la proteína de activación de fibroblafibro(FAP) y una variante de IL-2 que solo se une a IL-2R α α. | ||||
| GC74607 | Efineptakin alfa | 2026634-47-7 | >99.00% | |
Efineptakin alfa (NT-17) es una IL-7 humana recombinde acción prolongada. | ||||
| GC74612 | Epcoritamab | 2134641-34-0 | >99.00% | |
Epcoritamab (GEN3013) es un anticuerpo IgG1 biespecífico que redirige las células t hacia las células tumorales CD3 − CD20+. | ||||
| GC74614 | Eftozanermin alfa | 1820660-69-2 | >95.00% | |
Eftozanermin alfa (ABBV-621) es un agonista del receptor de ligandos (TRAIL-R) que induce apoptosis relacionado con el factor de necrosis tumoral de segunda generación. | ||||
| GC74620 | Zilovertamab vedotin | - | >98.00% | |
Zilovertamab vedotin (VLS-101) es un noveanticuerpo-fármaco conjuque comprende el anticuerpo monoclonal humanizilovertamab y la citotoxina antimicrotúbulos monometl vedotina. | ||||
